Novartis – Page 2 – Medical News Asia

Adjuvant dabrafenib plus trametinib FDA approved for BRAF V600E or V600K melanoma

30 April 2018/0 Comments/in US FDA Onc\Haem Approvals, Haematology, Oncology, Melanoma & Skin Cancer/by scienterrific

The FDA granted regular approval to dabrafenib (Tafinlar®, Novartis) and trametinib (Mekinist®, Novartis) in combination for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection.

Everolimus suspension approved in TSC-associated partial-onset seizures

10 April 2018/0 Comments/in Genitourinary Cancer, US FDA Onc\Haem Approvals, Oncology/by scienterrific

On April 10, the FDA approved everolimus tablets for oral suspension (Afinitor Disperz®, Novartis) for the adjunctive treatment of adult and pediatric patients ≥2 years with tuberous sclerosis complex (TSC)-associated partial-onset seizures.

FDA approved nilotinib for paediatric patients with newly diagnosed Ph+ CML-CP or Ph+ CML-CP resistant or intolerant to prior TKI

22 March 2018/0 Comments/in US FDA Onc\Haem Approvals, Uncategorised/by scienterrific

FDA approved nilotinib (TASIGNA, Novartis Pharmaceuticals Corporation) for pediatric patients 1 year of age or older with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) or Ph+ CML-CP resistant or intolerant to prior tyrosine-kinase inhibitor (TKI) therapy. More Information. March 22, 2018

Achieving Long-Term Survival in the First-Line Treatment of Metastatic Renal Cell Carcinoma; A Balancing Act of Efficacy and Side-Effects

8 January 2018/Enter your password to view comments./in Genitourinary Cancer, Uncategorised, Oncology, AE Management, Targeted Therapies/by Stijn van den Borne, MSc

There is no excerpt because this is a protected post.

Achieving Long-Term Survival in the First-Line Treatment of Metastatic Renal Cell Carcinoma; A Balancing Act of Efficacy and Side-Effects

8 January 2018/Enter your password to view comments./in Uncategorised/by Stijn van den Borne, MSc

There is no excerpt because this is a protected post.

Discontinuation, post-discontinuation monitoring criteria, and guidance for treatment re-initiation in patients taking nilotinib for Ph+ CML with a sustained molecular response

22 December 2017/0 Comments/in US FDA Onc\Haem Approvals, Uncategorised/by scienterrific

On 22 December, the FDA updated the product label for nilotinib (Tasigna®, Novartis) to include discontinuation, post-discontinuation monitoring criteria, and guidance for treatment re-initiation in patients taking nilotinib for Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) who have achieved a sustained molecular response (MR 4.5). More Information

Achieving Long-Term Survival in the First-Line Treatment of Metastatic Renal Cell Carcinoma; A Balancing Act of Efficacy and Side-Effects

29 November 2017/Enter your password to view comments./in Genitourinary Cancer, Oncology, Surgery/by Stijn van den Borne, MSc

There is no excerpt because this is a protected post.

Luminal Breast Cancer: can CDK4/6 Inhibition by Palbociclib Improve on Chemotherapy?

25 October 2017/1 Comment/in Breast Cancer, Oncology, Endocrine Therapy/by Stijn van den Borne, MSc

Can chemotherapy be avoided in women with hormone-sensitive breast cancer? This is a prominent question in the treatment of breast cancer around the globe.

ESMO16 Breast Cancer: Palbociclib, Ribociclib and Abemaciclib Data

9 November 2016/2 Comments/in Breast Cancer, Conferences, Oncology, Endocrine Therapy/by Stijn van den Borne, MSc

Cyclin-dependent Kinase 4 and 6 (CDK4/6) inhibitors have shown clinical activity in patients with endocrine-resistant metastatic breast cancer. During the European Society for Medical Oncology (ESMO) Annual Meeting 2016, significant updates on studies with CDK4/6 inhibitors ribociclib, palbociclib and abemaciclib were presented.

Ki67 in Breast Cancer: an overview

6 September 2016/3 Comments/in Breast Cancer, Oncology, Surgery, Targeted Therapies, Pathology, Translational Research/by Stijn van den Borne, MSc

Recent studies have shown new possible applications for Ki67. Huh et al. showed that low Ki67 levels in healthy breast tissue correlated with a lesser lifetime chance of breast cancer. Another study by Arnedos and colleagues concluded that palbociclib was able to invoke a significant Ki67-level drop. After a decade of Ki67-controversies, these results put the marker back in the spotlight.

Tag Archive for: Novartis